Gynecologic Oncology | Specialty

Dr. Oaknin on the Safety Profile of Dostarlimab in Endometrial Cancer

May 29th 2019

Ana Oaknin, MD, principal investigator, Gynecological Malignancies Group, Vall d’Hebron Institute of Oncology, head of Gynecologic Tumors Unit, senior medical oncologist and attending physician, Medical Oncology Department, Vall d’Hebron University Hospital, discusses the safety profile of dostarlimab (TSR-042) in patients with endometrial cancer.

Managing Obesity in Survivors of Gynecologic Cancer

May 25th 2019

With nearly 40% of the adult population in the Unites States classified as obese, gynecologic oncologists must be ready to address the specific needs and considerations for this population, including for patients who have entered survivorship.

FDA Grants LN-145 Breakthrough Designation for Cervical Cancer

May 24th 2019

The FDA has granted a breakthrough therapy designation to the tumor-infiltrating lymphocyte therapy LN-145 for the treatment of patients with recurrent, metastatic, or persistent cervical cancer with disease progression on or after chemotherapy.

Dr. Backes on the Utility of Sentinel Lymph Node Mapping in Cervical Cancer

May 24th 2019

Floor J. Backes, MD, associate professor, Division of Gynecologic Oncology, at The Ohio State University Comprehensive Cancer Center, discusses the utility of sentinel lymph node mapping in patients with cervical cancer.

Dostarlimab Demonstrates Efficacy in Endometrial Cancer

May 23rd 2019

Ana Oaknin, MD, provides insight into the implications of the GARNET trial and the promise of dostarlimab in endometrial cancer.

Dr. Hong on the Design of the InnovaTV 201 Trial in Cervical Cancer

May 23rd 2019

David S. Hong, MD, deputy director of the Department of investigational Cancer Therapeutics, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the design of the InnovaTV 201 trial in cervical cancer.

Dr. Hong on the Safety Profile of Tisotumab Vedotin in Cervical Cancer

May 16th 2019

David S. Hong, MD, deputy director of the Department of investigational Cancer Therapeutics, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the safety profile of tisotumab vedotin (HuMax-TF-ADC) in patients with cervical cancer.

Dr. Kim Discusses Minimally Invasive Surgery and Laparotomic Surgery in Cervical Cancer

May 14th 2019

Se Ik Kim, MD, research fellow, Department of Obstetrics and Gynecology, Seoul National University Hospital, discusses the use of minimally invasive surgery and laparotomic surgery in patients with cervical cancer.

Dr. Schlumbrecht on Investigational Treatment Strategies in Uterine Leiomyosarcoma

May 9th 2019

Matthew P. Schlumbrecht, MD, associate professor and co-director of Cancer Prevention and Control, Division of Gynecologic Oncology, Sylvester Comprehensive Cancer Center, University of Miami Health System, discusses investigational treatment strategies in uterine leiomyosarcoma.

The KEYNOTE-775 and Future of Endometrial Treatment

April 30th 2019

The Role of Lenvatinib Plus Pembrolizumab

April 30th 2019

The KEYNOTE-146 Trial

April 30th 2019

Advancements in Chemotherapy & PD-1 Inhibitor Therapies

April 30th 2019

Evolving Treatments for Advanced Endometrial Cancer

April 30th 2019

Dr. Zamarin on Priming Strategies in Ovarian Cancer

April 30th 2019

Dmitriy Zamarin, MD, PhD, medical oncologist at Memorial Sloan Kettering Cancer Center, discusses priming strategies in ovarian cancer.

Dr. Backes on Sentinel Lymph Node Mapping in Cervical Cancer

April 29th 2019

Floor J. Backes, MD, associate professor, Division of Gynecologic Oncology, at The Ohio State University Comprehensive Cancer Center, discusses the use of sentinel lymph node mapping in patients with cervical cancer.

EU Panel Backs Olaparib Approval for Frontline Maintenance in Ovarian Cancer

April 29th 2019

The European Committee for Medicinal Products for Human Use has recommended approval of olaparib as a frontline maintenance treatment for patients with BRCA-mutant advanced high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response following first-line platinum-based chemotherapy.

Molecular Markers: From Testing to Treatment in Ovarian Cancer

April 8th 2019

Britta Weigelt, PhD, discusses germline and somatic mutations in ovarian cancer that confer potential implications on treatment decisions, as well as those that carry an added cancer risk.

Frontline Approaches Fine-Tuned in Newly Diagnosed Ovarian Cancer

April 6th 2019

Paul Sabbatini, MD, clarifies where the field stands regarding the use of bevacizumab, intraperitoneal therapy, and a 3-week dosing schedule of chemotherapy versus a weekly dose-dense regimen in the frontline setting of newly diagnosed ovarian cancer.

Dr. Leitao on Eligibility for Neoadjuvant Chemotherapy in Advanced Ovarian Cancer

April 2nd 2019

Mario M. Leitao Jr, MD, FACOG, FACS, fellowship director, gynecology service, director, Minimal Access and Robotic Surgery Program, Department of Surgery, Memorial Sloan Kettering Cancer Center, discusses patient eligibility for neoadjuvant chemotherapy in advanced ovarian cancer.